Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07299409
First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
A Phase II Study of First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.
Sponsor: British Columbia Cancer Agency
Interventions
Sacituzumab Govitecan (SG)
Updated 1 time since 2026 Last updated: Dec 9, 2025 Started: Dec 31, 2025 Primary completion: Aug 31, 2027 Completion: Mar 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Advanced Triple Negative Breast Cancer and Breast Cancer, this trial is actively recruiting participants. The trial is conducted by British Columbia Cancer Agency and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- British Columbia Cancer Agency
- Nathalie Levasseur
Data source: British Columbia Cancer Agency
For direct contact, visit the study record on ClinicalTrials.gov .